These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 5397407)

  • 1. [Glucagon test in diabetics: its significance and its changes after treatment with Glybenclamide].
    Adezati L; De Lorenzi F; Prando R; Fresco G; Pagliaini R; Amore R
    Acta Diabetol Lat; 1969; 6(2):247-82. PubMed ID: 5397407
    [No Abstract]   [Full Text] [Related]  

  • 2. Circadian variations of carbohydrate tolerance in maturity onset diabetics treated with sulfonylureas.
    Göschke H; Denes A; Girard J; Collard F; Berger W
    Horm Metab Res; 1974 Sep; 6(5):386-91. PubMed ID: 4417576
    [No Abstract]   [Full Text] [Related]  

  • 3. [HB 419 (Glybenclamide) in the treatment of diabetes mellitus].
    Singh I; Srivastava MC
    Acta Diabetol Lat; 1969; 6(2):222-40. PubMed ID: 5397406
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of the obese diabetic. A comparative study of placebo, sulfonylurea and phenformin.
    Abramson E; Arky RA
    Metabolism; 1967 Mar; 16(3):204-12. PubMed ID: 5336062
    [No Abstract]   [Full Text] [Related]  

  • 5. Diurnal change of plasma insulin in diabetics with sulfonylurea treatment.
    Toyota T
    Tohoku J Exp Med; 1969 Aug; 98(4):345-56. PubMed ID: 5346206
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the clinical use of biguanides].
    Haese E
    Arzneimittelforschung; 1969 Apr; 19(4):633-8. PubMed ID: 5819164
    [No Abstract]   [Full Text] [Related]  

  • 7. [Insulin-stimulating properties of Glybenclamide (HB 419) in healthy subjects. Comparative studies with tolbutamide].
    Brunetti P; Cozzolino G; Santeusanio F; Arena D; De Ciuceis P; Marri G; Migliorini E
    Acta Diabetol Lat; 1969; 6(2):283-98. PubMed ID: 5397408
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evidence of a reduction of insulin secretion in diabetes with or without obesity. Discussion of the therapeutic use of biguanides].
    Luyckx A; Lefebvre P
    Ann Endocrinol (Paris); 1969; 30(6):717-30. PubMed ID: 5384987
    [No Abstract]   [Full Text] [Related]  

  • 9. [Influence of therapy and adjustment of diabetics with xanthine nicotinate].
    Hahn J; Kaffarnik H
    Med Klin; 1969 May; 64(22):1042-5. PubMed ID: 5800195
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of metformin on plasma glucose, insulin, FFA, glucagon, growth hormone and cortisol responses to oral glucose in subjects with chemical diabetes.
    Giugliano D; Torella R; Improta L; Scognamiglio G
    Farmaco Prat; 1979 Jan; 34(1):32-41. PubMed ID: 378687
    [No Abstract]   [Full Text] [Related]  

  • 11. [Normal plasma free fatty acid (C 16 -C 18 ) values in diabetics after treatment with an oral hypoglycemizing agent].
    Bertolini AM; Santagostino A
    Minerva Med; 1972 Mar; 63(20):1145-9. PubMed ID: 5018858
    [No Abstract]   [Full Text] [Related]  

  • 12. [Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics under monotherapy with various sulfonylureas].
    Happ J; Beyer J; Nest E; Fröhlich A; Althoff PH; Schöffling K
    Arzneimittelforschung; 1974 Aug; 24(8):1228-34. PubMed ID: 4214173
    [No Abstract]   [Full Text] [Related]  

  • 13. [Blood levels of glucagon, insulin and nonesterified fatty acids after arginine stimulation in obese diabetics].
    Cucinotta D; Quartarone M; Saitta A; Sardo A; Squadrito G
    Boll Soc Ital Biol Sper; 1978 Nov; 54(22):2290-6. PubMed ID: 754729
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum insulin, glucose, and lipid levels among mild diabetics in relation to incidence of vascular complications.
    Elkeles RS; Lowy C; Wyllie AD; Young JL; Fraser TR
    Lancet; 1971 May; 1(7705):880-3. PubMed ID: 4102026
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and metabolic observations with a new synthetic oral antidiabetic agent, glipizide.
    D'Onofrio F; Pempinello R; Romis L
    Arzneimittelforschung; 1972 Nov; 22(11):1879-81. PubMed ID: 4679059
    [No Abstract]   [Full Text] [Related]  

  • 16. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM; Tabaru A; Nakamura H; Fukumitsu KI; Akiyama T; Otsuki M
    Metabolism; 2000 Sep; 49(9):1167-75. PubMed ID: 11016899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic diabetes mellitus in hypertensive patients of normal weight. Glucose tolerance and serum levels of insulin and nonesterified fatty acids in essential hypertension.
    Dieterle P; Fehm H; Ströder W; Henner J; Bottermann P; Schwarz K
    Ger Med Mon; 1968 Oct; 13(10):478-83. PubMed ID: 5707015
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mechanism of action of gliquidone (author's transl)].
    Zilker T; Ermler R; Henderkott U; Bottermann P
    Dtsch Med Wochenschr; 1975 Aug; 100(35):1733-4, 1739-41. PubMed ID: 808405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of serum insulin during fasting and glucose loading before and after treatment of diabetes].
    Kosaka K; Hagura R; Ogawara H
    Dtsch Med J; 1970 Apr; 21(8):554-64. PubMed ID: 5510200
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development, after oral dose of carbutamide in diabetics, of plasma levels of glucose, insulin, free fatty acids and sulfonamide].
    Mantel O; Fiet J; Dreux C; Canivet J
    Journ Annu Diabetol Hotel Dieu; 1969; 10():293-300. PubMed ID: 5376987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.